These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 106399)

  • 1. Regulation of immune response to tumor antigen: interference with syngeneic tumor immunity by anti-IA alloantisera.
    Perry LL; Dorf ME; Benacerraf B; Greene MI
    Proc Natl Acad Sci U S A; 1979 Feb; 76(2):920-4. PubMed ID: 106399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo effects of anti-Ia alloantisera. I. Elimination of specific suppression by in vivo administration of antisera specific for I-J controlled determinants.
    Pierres M; Germain RN; Dorf ME; Benacerraf B
    J Exp Med; 1978 Mar; 147(3):656-66. PubMed ID: 75939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the immune response to tumor antigens. III. Characterization of thymic suppressor factor(s) produced by tumor-bearing hosts.
    Greene MI; Fujimoto S; Sehon AH
    J Immunol; 1977 Aug; 119(2):757-64. PubMed ID: 69667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H-2 antigens and tumour-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumour: their influence on the generation in vitro and in vivo of the specific anti-tumour immune response.
    Pérez M; Garrido A; Algarra I; Caballero A; Delgado C; Collado MD; Fernández-Cruz E; Garrido F
    Exp Clin Immunogenet; 1989; 6(3):204-18. PubMed ID: 2631798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of a primary in vivo antibody response by alloantisera against gene products of the I region of the H-2 complex.
    Pierres M; Germain RN; Dorf ME; Benacerraf B
    Proc Natl Acad Sci U S A; 1977 Sep; 74(9):3975-9. PubMed ID: 410029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated growth of syngeneic tumors in mice treated with methylcholanthrene.
    Lill PH; Jessup JM; Kripke ML
    Int J Cancer; 1978 Apr; 21(4):511-5. PubMed ID: 669850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
    Plata F; Jongeneel V; Cerottini JC; Brunner KT
    Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of graft-versus-host reaction on the immune response to alloantigens and growth of a syngeneic tumor.
    Zaleski M
    Exp Hematol; 1975 Jan; 3(1):12-21. PubMed ID: 238866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the immune response to tumor antigen. VI. Differential specificities of suppressor T cells or their products and effector T cells.
    Greene MI; Perry LL
    J Immunol; 1978 Dec; 121(6):2363-6. PubMed ID: 82582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced syngeneic tumor destruction by in vivo inhibition of suppressor T cells using anti-I-J alloantiserum.
    Perry LL; Benacerraf B; McCluskey RT; Greene MI
    Am J Pathol; 1978 Aug; 92(2):491-506. PubMed ID: 307911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune mechanisms in organ allograft rejection. III. Cellular and humoral immunity in rejection of organ allografts transplanted across MHC subregion disparity RT1.B (RT1.D).
    Lowry RP; Gurley KE
    Transplantation; 1983 Oct; 36(4):405-11. PubMed ID: 6353708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.
    Roberts LK
    J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the immune response to tumor antigen.
    Greene MI; Perry LL; Benacerraf B
    Am J Pathol; 1979 Apr; 95(1):159-69. PubMed ID: 373460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of tumor immunity against syngeneic tumors in mice by beta-carotene.
    Tomita Y; Himeno K; Nomoto K; Endo H; Hirohata T
    J Natl Cancer Inst; 1987 Apr; 78(4):679-81. PubMed ID: 3470543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
    Henderson LA; Ciavarra R; Riblet R; Forman J
    J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro reactivity of splenic lymphocytes from normal and UV-irradiated mice against syngeneic UV-induced tumors.
    Fortner GW; Kripke ML
    J Immunol; 1977 Apr; 118(4):1483-7. PubMed ID: 66296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of stimulation in murine mixed lymphocyte cultures with an alloantiserum directed against a shared Ia determinant.
    Schwartz RH; Fathman CG; Sachs DH
    J Immunol; 1976 Apr; 116(4):929-35. PubMed ID: 56405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and stimulatory cell type requirements for inducing class I major histocompatibility complex alloantigen-specific in vivo cytotoxic T cell immunity.
    Mizoguchi K; Nakashima I; Isobe K; Ando K; Nagase F; Kato N; Kawashima K; Shimokata K; Hasegawa Y
    Eur J Immunol; 1985 May; 15(5):487-94. PubMed ID: 3873341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.